Tema Oncology ETF (NASDAQ:CANC – Get Free Report) was the target of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 27,461 shares, a growth of 79.6% from the June 15th total of 15,293 shares. Based on an average daily volume of 67,600 shares, the short-interest ratio is currently 0.4 days. Currently, 0.6% of the company’s shares are sold short.
Institutional Trading of Tema Oncology ETF
Hedge funds have recently bought and sold shares of the stock. Roxbury Financial LLC bought a new stake in shares of Tema Oncology ETF in the 1st quarter valued at about $34,000. Jane Street Group LLC acquired a new position in shares of Tema Oncology ETF in the first quarter valued at approximately $213,000. LPL Financial LLC bought a new position in shares of Tema Oncology ETF during the fourth quarter worth approximately $278,000. Flow Traders U.S. LLC acquired a new stake in Tema Oncology ETF during the 3rd quarter worth approximately $630,000. Finally, Thrivent Financial for Lutherans lifted its holdings in Tema Oncology ETF by 891.1% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,461,649 shares of the company’s stock worth $50,747,000 after purchasing an additional 1,314,177 shares during the last quarter.
Tema Oncology ETF Stock Up 1.4%
Shares of CANC traded up $0.56 during trading hours on Friday, reaching $41.07. The stock had a trading volume of 9,418 shares, compared to its average volume of 33,625. Tema Oncology ETF has a 52 week low of $25.12 and a 52 week high of $42.63. The firm has a 50-day moving average of $38.77 and a 200 day moving average of $37.47. The company has a market cap of $194.67 million, a P/E ratio of 20.39 and a beta of 0.67.
Tema Oncology ETF Company Profile
The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.
See Also
- Five stocks we like better than Tema Oncology ETF
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Tema Oncology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tema Oncology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
